Sidley represented Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, in its US$77 million Series B financing. The proceeds will support completion of the CROSSCHECK-001 Phase 1 clinical trial of the company’s lead program, CBX-250, and accelerate development of additional T-Bolt™ immunotherapies.
Crossbow is developing a broad portfolio of novel T-cell engager therapies that target peptide human leukocyte antigen on cancer cells using T-cell receptor mimetic antibodies. These investigational T-Bolt™ molecules are designed to address a wide range of malignancies and have the potential to expand the reach of antibody therapies across many cancer proteins.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.